Meridian Bioscience Comments on FDA Matter Involving its Subsidiary, Magellan Diagnostics
CINCINNATI, May 17, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO). Meridian Bioscience, Inc.’s subsidiary, Magellan Diagnostics, Inc., is currently working with the U.S. Food and Drug Administration (FDA) regarding use of venous blood (blood drawn from a vein) with its LeadCare Testing Systems. Magellan’s primary product is the LeadCare II, a point-of-care (CLIA-waived) blood […]